Negative Legionella Urinary Antigen, Now What?

Expanding the Legionella Diagnostic Toolkit in a Changing Epidemiological Landscape

As microbiology laboratories across the UK enter the spring and summer months, the familiar rise in respiratory presentations brings renewed focus on atypical pathogens. Among these, Legionella remains a significant cause of severe community-acquired pneumonia (CAP), often requiring rapid clinical decision-making to reduce morbidity and mortality.

However, evolving epidemiological patterns, particularly the increasing recognition of non-pneumophila species, raise an important question for diagnostic laboratories: What happens when standard Legionella testing returns negative, but clinical suspicion remains high?

The Diagnostic Gap in Legionella Testing

For decades, frontline diagnostics for Legionnaires’ disease have relied heavily on urinary antigen tests targeting Legionella pneumophila (L. pneumophila) serogroup 1. While this approach has been instrumental in improving early detection, it is inherently limited in scope.

Evidence from surveillance data and clinical studies shows that non-pneumophila species, most notably Legionella longbeachae (L. longbeachae), are increasingly recognised as clinically relevant pathogens. According to the UK Health Security Agency (UKHSA), reported cases of L. longbeachae infection in England and Wales have risen in recent years, with notable increases compared to historical baselines¹.

Crucially, standard urinary antigen tests do not detect L. longbeachae, creating a diagnostic blind spot that may delay appropriate treatment.

Why a Negative Legionella Test May Not Tell the Full Story

A negative urinary antigen result is often interpreted as evidence against Legionella infection. Yet clinical and epidemiological data suggest that this assumption can be misleading.

The NHS case study² of a gardener with severe pneumonia highlights this challenge. Despite classic symptoms consistent with Legionnaires’ disease, initial testing failed to identify the causative organism. Only after further investigation was L. longbeachae confirmed, underscoring the limitations of relying solely on conventional diagnostics.

This is not an isolated issue. UK guidance and emerging case evidence highlight the need to consider L. longbeachae in patients with severe community-acquired pneumonia – particularly where there is relevant environmental exposure and negative initial Legionella testing.

Failure to detect these infections early may contribute to delays in targeted antimicrobial therapy, which is associated with poorer outcomes in severe cases³.

Seasonal Exposure and Emerging Risk Profiles

International data, particularly from Australia and New Zealand, suggest that L. longbeachae may account for a substantial proportion of Legionella infections in certain settings, raising the possibility that current UK figures underestimate its true burden^4,5.

Expanding the Diagnostic Toolkit

When Legionella infection is suspected despite negative initial testing, laboratories often turn to alternative diagnostic approaches:

• PCR assays – offering broader species detection, although not always universally available or standardised
• Culture – the reference method, but slow and technically demanding
• Serology – of limited value in acute clinical settings

While each of these methods plays an important role, they are not always well aligned with the rapid turnaround times required in the management of severe CAP.

This highlights a growing need for diagnostic strategies that combine speed with broader species coverage, enabling earlier clinical decision-making without compromising accuracy.

Alongside molecular and culture-based approaches, there is increasing interest in rapid urinary antigen tests capable of detecting multiple Legionella species within a single assay. Traditional tests have largely focused on L. pneumophila serogroup 1, but newer approaches aim to extend detection to species such as L. longbeachae, while maintaining rapid turnaround times.

The value of these developments lies in their ability to preserve the simplicity and accessibility of urine-based testing, while improving diagnostic coverage in patients with relevant environmental exposures or severe disease. As Legionella epidemiology continues to evolve, broadening the scope of rapid front-line diagnostics may help laboratories support earlier and more confident clinical decisions, particularly in time-critical settings such as intensive care.

One example of this approach is the ImmuView® urinary antigen test, which enables detection of both L. pneumophila and L. longbeachae within a single rapid assay and is available in the UK through Una Health.

Implications for Microbiology Laboratories

The evolving epidemiology of Legionella presents both a challenge and an opportunity for UK microbiology services.

Key considerations include:

• Re-evaluating testing algorithms: Particularly for ICU patients with severe CAP
• Incorporating exposure history: Routine prompts for gardening or compost exposure may improve case detection
• Aligning with national guidance: UKHSA recommendations increasingly emphasise the need to consider non-pneumophila species
• Balancing speed and breadth: Rapid diagnostics remain critical, but must reflect the diversity of circulating pathogens

Ultimately, improving detection of Legionella infections, especially those caused by less commonly identified species, has the potential to enhance patient outcomes, reduce unnecessary antimicrobial use, and strengthen public health surveillance.

Looking Ahead

As Legionella epidemiology continues to shift, diagnostic paradigms must evolve in parallel. The traditional focus on L. pneumophila alone may no longer be sufficient in all clinical contexts.

For microbiology laboratories, the question is no longer simply how quickly Legionella can be detected, but how comprehensively.

Ensuring that diagnostic pathways reflect real-world exposure risks and emerging species trends will be essential in supporting clinicians, improving patient care, and maintaining confidence in laboratory results.

---

References

1. UK Health Security Agency. Legionellosis in residents of England and Wales, 2017 to 2023. GOV.UK.
2. Breaking ground: a rare case of Legionella longbeachae in a gardener – https://nshcs.hee.nhs.uk/research-projects/breaking-ground-a-rare-case-of-legionella-longbeachae-in-a-gardener/
3. National Institute for Health and Care Excellence (NICE). Pneumonia (community-acquired): antimicrobial prescribing.
4. Whiley H, Bentham R. Legionella longbeachae and legionellosis. Emerging Infectious Diseases. 2011;17(4):579–583.
5. Phin N et al. Epidemiology and clinical management of Legionnaires’ disease. Lancet Infectious Diseases. 2014;14(10):1011–1021.

---